Plain-English translation of NCT06946225 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This early-stage trial is testing a new combination approach called paired with an mRNA-based vaccine () for people with advanced melanoma or synovial sarcoma that hasn't responded to previous treatments. is a type of cell therapy—doctors take some of your immune cells, train them in the lab to recognize and attack cancer cells, and then put them back into your body. The mRNA vaccine is designed to boost your immune system's ability to keep fighting the cancer.
Current treatments don't work for everyone with these cancers, especially after the cancer has spread or become resistant to earlier therapies. This trial is exploring whether combining cell therapy with a personalized vaccine might give patients a new option when standard treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You would undergo a procedure called leukapheresis where doctors collect some of your white blood cells, which are then sent to a lab to be modified and expanded. While that's happening, you'll receive some preparatory chemotherapy. Then you'll receive an infusion of the modified cells back into your body, followed by doses of the mRNA vaccine over several weeks. You'll have regular visits for blood tests, scans, and check-ups to monitor how the treatment is working and how you're tolerating it.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States